News|Articles|November 16, 2026

FDA Approves Obinutuzumab for Primary Membranous Nephropathy

Listen
0:00 / 0:00

Key Takeaways

  • Regulatory clearance makes obinutuzumab the first disease-specific approved option for primary membranous nephropathy, supported by breakthrough therapy, orphan drug, and priority review designations.
  • MAJESTY demonstrated superior complete remission at week 104 with obinutuzumab versus tacrolimus (37% vs 6%; adjusted difference 31 percentage points; P<.001) using proteinuria and eGFR-based criteria.
SHOW MORE

The anti-CD20 antibody is the first drug approved specifically for the disease, based on phase 3 MAJESTY data showing higher remission vs tacrolimus.

The FDA has approved obinutuzumab (Gazyva; Genentech) to induce remission of proteinuria in adults with primary membranous nephropathy who are at risk of disease progression, making it the first drug approved specifically for the condition. For pharmacists, the approval brings a type II anti-CD20 monoclonal antibody and its boxed warning for hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML) into a disease that has been managed with off-label immunosuppressants such as tacrolimus (Prograf; Astellas Pharma).1

The agency announced the approval on November 13, 2026. The application previously received breakthrough therapy, orphan drug, and priority review designations. Obinutuzumab was previously approved for certain cancers, active lupus nephritis, and childhood-onset idiopathic nephrotic syndrome.1

Obinutuzumab Outperforms Tacrolimus on Complete Remission

The approval is based on MAJESTY (NCT04629248), a phase 3, randomized, open-label, multicenter trial that randomly assigned 142 adults with primary membranous nephropathy 1:1 to intravenous obinutuzumab or oral tacrolimus. The primary end point was complete remission at week 104, defined as a urine protein-to-creatinine ratio of 0.3 g/g or lower with a stable estimated glomerular filtration rate (eGFR), without rescue therapy, treatment failure, or early discontinuation.1,2

At week 104, complete remission occurred in 26 of 71 patients receiving obinutuzumab and 4 of 70 receiving tacrolimus (37% vs 6% with multiple imputation; adjusted difference, 31 percentage points; 95% CI, 18-44; P<.001). Complete or partial remission at week 104 and complete remission at week 76 also favored obinutuzumab; however, the trial did not show a significant difference in sustained eGFR reduction of at least 30%, so later end points in the testing hierarchy, including duration of complete remission and patient-reported fatigue, were not formally tested.2

Genentech reported overall remission at week 104 of 50% with obinutuzumab versus 12.9% with tacrolimus and complete remission at week 76 of 36.1% versus 8.6%.3

Where Obinutuzumab May Fit

In primary membranous nephropathy, the immune system attacks the glomeruli, causing large amounts of protein to leak into the urine. Complications can include high cholesterol, high blood pressure, severe swelling, fatigue, and kidney failure.1 According to Genentech, up to 30% of untreated patients progress to kidney failure within 10 years, and the estimated US incidence is 1.2 per 100,000 people per year.3

The phospholipase A2 receptor is the target antigen in 70% to 80% of cases. Roughly one-third of patients remit spontaneously, and immunosuppression is guided by Kidney Disease: Improving Global Outcomes risk stratification. Rituximab is the preferred choice for moderate- and high-risk disease, while calcineurin inhibitors have been relegated to second or third line because of potential nephrotoxicity and high relapse rates after discontinuation. A recent review noted that approximately 20% to 40% of patients treated with rituximab are resistant and that obinutuzumab is being increasingly studied in the disease.4

Safety and Counseling Considerations

In MAJESTY, grade 3 or higher adverse events (AEs) occurred in 22% of patients receiving obinutuzumab and 19% receiving tacrolimus, and serious AEs occurred in 17% and 14%, respectively. Infection rates were 61 and 57 per 100 patient-years, with serious infections at 3 and 4 per 100 patient-years. Adverse drug reactions with obinutuzumab included infusion-related reactions, respiratory tract infections, and neutropenia. One patient in each group died during escape therapy.2

The FDA listed infusion-related reactions and upper respiratory tract infection as the most common AEs in the membranous nephropathy study.1 Pharmacists reviewing orders should confirm that patients have been screened for HBV before treatment and are monitored during and after therapy; obinutuzumab is not for patients with active HBV liver disease. Other counseling points include avoiding live vaccines, using effective contraception during treatment and for 6 months after, and avoiding breastfeeding during treatment and for 6 months after the last dose. Neutropenia and thrombocytopenia are also listed among the drug's serious risks.3

REFERENCES
1. FDA approves first drug to treat adults with primary membranous nephropathy. News release. FDA. November 13, 2026. Accessed November 16, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-adults-primary-membranous-nephropathy
2. Fervenza FC, Hou FF, Hao CM, et al; MAJESTY Trial Investigators. Obinutuzumab or tacrolimus in primary membranous nephropathy. N Engl J Med. 2026;395(10):959-971. doi:10.1056/NEJMoa2602678
3. Genentech's Gazyva becomes the first FDA-approved treatment for primary membranous nephropathy. News release. Genentech. November 15, 2026. Accessed November 16, 2026. https://www.gene.com/media/press-releases/15143/2026-11-15/genentechs-gazyva-becomes-the-first-fda-
4. Filippone EJ, Farber JL. Contemporary review of primary membranous nephropathy. Front Immunol. 2026;17. doi:10.3389/fimmu.2026.1836347

Related to this article